News + Resources
Keep up with the latest
Featured
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
CRISPR 2.0, the Next Generation
June 21, 2024
Aspen Ideas: Health
CRISPR 2.0, the Next Generation
June 21, 2024
All Stories
News
Scribe, Biogen Partner to Develop Gene Therapy for ALS, Other Neurological Diseases
October 8, 2020
ALS News Today
Read Now
Press Release
Scribe, Biogen Partner to Develop Gene Therapy for ALS, Other Neurological Diseases
October 8, 2020
ALS News Today
Read Now
News
Scribe Therapeutics, Biogen collaborate to develop CRISPR-based genetic medicines
October 7, 2020
Pharmaceutical Business Review
Read Now
Press Release
Scribe Therapeutics, Biogen collaborate to develop CRISPR-based genetic medicines
October 7, 2020
Pharmaceutical Business Review
Read Now
News
Scribe Therapeutics emerges with $20M, Biogen pact to clear CRISPR hurdles
October 7, 2020
Fierce Biotech
Read Now
Press Release
Scribe Therapeutics emerges with $20M, Biogen pact to clear CRISPR hurdles
October 7, 2020
Fierce Biotech
Read Now
News
Starting with Biogen deal in ALS, Scribe planning a new chapter in CRISPR story
October 7, 2020
BioWorld
Read Now
Press Release
Starting with Biogen deal in ALS, Scribe planning a new chapter in CRISPR story
October 7, 2020
BioWorld
Read Now
News
Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines for Neurological Diseases Including ALS
October 6, 2020
Read Now
Press Release
Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines for Neurological Diseases Including ALS
October 6, 2020
Read Now